Identification of in silico predictive models
Ariana’s services for biomarkers data analysis identifies and optimizes multi-markers predictive signatures (MAAT, Multi Analyte Algorithmic Tests). Its proprietary technology KEM® systematically combines all available markers and generates the most relevant and robust predictive models. These services can be easily applied to exploratory research phases of new predictive models as well as biomarkers validation phases for diagnostic tools or identification of companion markers for targeted therapies.
Ariana is currently developing a set of software combined with laboratory tests that enable personalized treatment selection in oncology. Ariana has also developed algorithms that have been embedded in personalized medicine diagnostic tools. Ariana conducts these projects through partnerships with pharmaceutical and diagnostic companies as well as academic partners.
Ariana’s technology and expertise are also offered through consulting and data analysis services as well as licensing agreements for the KEM® software suite. Ariana’s team is multidisciplinary and highly experienced with degrees in Medicine, Computational Biology, Biostatistics, Biomathematics and Artificial Intelligence. Founded in 2003 as a spin-off of Institut Pasteur, Ariana is based in Paris and has a fully owned subsidiary in the U.S. It has entered into a distribution agreement with a Japanese provider, CT-LS.